$PBLS News

Parabilis Medicines: Bullish On Zolucatetide's Broad Oncology Potential

Parabilis Medicines, Inc. (PBLS) Discusses Updated Zolucatetide Data in Desmoid Tumors and Phase III Path Transcript

Parabilis Medicines, Inc. (PBLS) Discusses Updated Zolucatetide Data in Desmoid Tumors and Phase III Path - Slideshow

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors

HC Wainwright & Co. Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $40

Parabilis Medicines (PBLS) Stock May Trade At A Premium Despite Fresh Zolucatetide Trial Updates

Parabilis Medicines (PBLS) Could Be 39% Undervalued As Zolucatetide Trial Expands

What Does Parabilis Medicines (PBLS) Expanding Zolucatetide Into FAP Mean?

Parabilis: $1B+ Rare-Disease Foundation Leaves The Big Oncology Pipeline For Free

Parabilis Soars 13% on Upcoming ESMO Data for “First-in-Class” Desmoid Tumor Drug

Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026

Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis

Parabilis Medicines Initiates Dose-Ranging Clinical Cohort Evaluating Zolucatetide In Patients With Familial Adenomatous Polyposis As Part Of Ongoing Phase 1/2 Clinical Trial

Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors

Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform

Parabilis Medicines Q2 EPS $(2.32) Misses $(0.08) Estimate, Sales $148.000K Miss $25.000M Estimate

Leerink Partners Initiates Coverage On Parabilis Medicines with Outperform Rating, Announces Price Target of $40